An Open-label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of AR-13324 Ophthalmic Solution, 0.02% in Healthy Volunteers
Latest Information Update: 16 Jul 2015
At a glance
- Drugs Netarsudil (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Pharmacokinetics
- Sponsors Aerie Pharmaceuticals
- 01 May 2015 Results published in the American Journal of Ophthalmology.
- 04 Dec 2013 New source identified and integrated: ClinicalTrials.gov record NCT01997879 .
- 04 Dec 2013 New source identified and integrated: ClinicalTrials.gov record NCT01997879 .